Pain Management · OpioidRegulatory Approvalcommercialnear-term

FDA Grants Approval for Methadone Hydrochloride ANDA212093 by Lannett Co Inc

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/24/2026, 6:03:48 AM

Assessment confidence: 55% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Lannett's ANDA for Methadone Hydrochloride signifies increased competition in the opioid pain management market. This could impact pricing strategies and market share for existing players in this therapeutic area. Regulatory context from FDA (FDA AP — METHADONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 11 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Lannett's entry on market share and pricing strategies for existing methadone products. The strongest clinical anchor is Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia (ClinicalTrials.gov), sub-indication match (pain). In pain, 7 regulatory and 1 competitive items passed relevance filtering for Methadone Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride) (Humanexa Signals) — sponsor/company relevance (novartis). This approval allows Lannett to enter the market for Methadone Hydrochloride, potentially increasing competition in the opioid pain management segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHADONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (methadone hydrochloride); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes for existing products.

Key Opportunities

Lannett's entry may lead to price pressures and shifts in market share among current methadone suppliers, affecting revenue projections.
Portfolio teams should assess the impact of Lannett's entry on market share and pricing strategies for existing methadone products.

What Would Change This Assessment

This becomes more urgent if Monitor Lannett's market launch timeline and any subsequent competitive responses from other manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE INTENSOL (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Endometriosis Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of Dry Needling Plus Vibration on Myofascial Trigger Points in Individuals With Nonspecific Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride)
Humanexa Signalsmedium relevance
Sponsor/company relevance (Novartis)
FDA Grants Priority Review for LEQEMBI Supplement Application
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Targeting post-translational modifications by traditional Chinese medicine in cerebral ischemia-reperfusion injury: Recent advances.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Acute kidney injury after cytoreductive surgery and HIPEC: incidence and timing in a 10-year single-center cohort.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Methadone Hydrochloride

Commercial impact

medium

Lannett's entry may lead to price pressures and shifts in market share among current methadone suppliers, affecting revenue projections.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes for existing products.

What to watch

Monitor Lannett's market launch timeline and any subsequent competitive responses from other manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.